The forms
Four common niacin-related supplements exist, each with different properties:
| Form | GPR109A activation | NAD+ pathway | Flush | Typical dose |
|---|---|---|---|---|
| Nicotinic acid (niacin) | Yes | Preiss-Handler | Yes | 500mg-3g |
| Niacinamide (nicotinamide) | No | Salvage | No | 500mg-1.5g |
| NR (nicotinamide riboside) | No | Salvage → NMN | No | 250-500mg |
| NMN (nicotinamide mononucleotide) | No | Direct to NAD+ | No | 250-500mg |
This distinction is not a minor detail. It is the central fact that determines whether supplementation can activate immune regulatory pathways through GPR109A.
Why the form matters
Nicotinic acid is the only form that activates GPR109A. This receptor is the mechanism behind:
- Regulatory T cell promotion
- Anti-inflammatory macrophage polarization
- Prostaglandin D2-mediated immune signaling
- The niacin flush itself (which is GPR109A-mediated)
If a niacin supplement does not cause a flush, it is not activating GPR109A. This is not a side effect to be avoided — it is the signal that the immune-regulatory pathway is being activated.
NAD+ pathway differences
Nicotinic acid enters NAD+ synthesis via the Preiss-Handler pathway (nicotinic acid → NaMN → NaAD → NAD+). All other forms use the salvage pathway or direct conversion.
Supplementation of nicotinic acid and its derivatives shows that nicotinic acid up-regulates cellular NAD+ levels more effectively than nicotinamide derivatives in cultured human epidermal keratinocytes. This may reflect tissue-specific differences in pathway enzyme expression.
Bacteria in the gut can convert nicotinamide to nicotinic acid via PNCa, improving liver function in mouse models — suggesting that the gut microbiome mediates some form conversion. But this conversion is unreliable and microbiome-dependent.
The "flush-free" problem
Sustained-release niacin formulations and "flush-free" versions (often inositol hexaniacinate) were developed to avoid the flush. A direct comparison study showed that sustained-release niacin caused hepatotoxicity in 52% of patients while immediate-release niacin caused 0% liver toxicity.
The flush-free versions likely have reduced GPR109A activation — which is precisely the mechanism relevant for immune effects. They trade the therapeutic signal for comfort.
What remains unknown
- Relative immune potency: No head-to-head trial has compared nicotinic acid vs. niacinamide vs. NR for autoimmune outcomes in humans.
- Gut conversion rate: What fraction of oral niacinamide is converted to nicotinic acid by gut bacteria in a typical human?
- NR immune effects: NR may have immune effects through NAD+ repletion alone, without GPR109A. Whether these are clinically meaningful is untested.
- Combination potential: Whether nicotinic acid (for GPR109A) combined with NR (for efficient NAD+ repletion) produces additive benefits.